<DOC>
	<DOCNO>NCT03102918</DOCNO>
	<brief_summary>We aim determine Epidiolex 's promise pharmacotherapy cannabis use disorder . We hypothesize Epidiolex , add medical management , result great reduction marijuana use compare placebo measure 2 primary outcome measure : 1 ) quantitative THC level 2 ) self-report Timeline Follow Back . Secondary outcome measure include treatment retention , patient satisfaction , cannabis withdrawal , cannabis craving , depressive symptom , anxiety symptom , , compliance , cigarette use .</brief_summary>
	<brief_title>Cannabidiol Pharmacotherapy Adults With Cannabis Use Disorder</brief_title>
	<detailed_description>We conduct Stage 1 pilot feasibility study McLean Hospital begin evaluate Epidiolex pharmacotherapy adult cannabis use disorder . In randomized , double-blind , placebo-controlled trial , cannabis-dependent subject age 18-65 receive medical management 6-week period , half receive Epidiolex treatment half receive placebo . Participants receive either 800 mg Epidiolex placebo 6-week treatment period . Following treatment completion , participant follow-up visit 10 14 week . Primary outcome include self-report cannabis smoke result quantitative urine drug screen cannabis . Secondary outcome measure include treatment retention , patient satisfaction , cannabis withdrawal , cannabis craving , depressive symptom , anxiety symptom , compliance , cigarette use .</detailed_description>
	<mesh_term>Disease</mesh_term>
	<mesh_term>Marijuana Abuse</mesh_term>
	<criteria>1 ) Age range 1865 year ; 2 ) DSM 5 diagnosis cannabis use disorder , base Structured Clinical Interview DSM 5 ( SCID5 ) ; 3 ) express desire quit cannabis use within next 30 day ; 4 ) use cannabis ≥4 day within past 30 day ( i.e. , average ≥1 day per week ) ; 5 ) woman childbearing age , negative pregnancy test screening agreement use adequate contraception prevent pregnancy monthly pregnancy test ; men , contraception discuss begin study study physician ; 6 ) consent u communicate prescribe clinician ; 7 ) furnish name 2 locator , would assist study staff locate study period ; 8 ) live close enough McLean Hospital attend study visit ; 9 ) plan stay Boston area next 3 month ; 10 ) willing able sign inform consent . 1 ) Current diagnosis drug alcohol dependence ( exclude nicotine ) ; 2 ) recent ( within 3 month ) significant cardiac disease ; 3 ) current serious psychiatric illness history psychosis , schizophrenia , bipolar type I disorder ; 4 ) current medical condition ( include significant laboratory abnormality , abnormal liver function test ) could prevent regular study attendance ; 5 ) mental retardation organic mental disorder ; 6 ) acutely dangerous suicidal behavior ; 7 ) currently residential treatment set substance use monitor restrict , since restrict access drug could represent important confound variable ; 8 ) pregnant , nursing , , woman childbearing potential , use form birth control judge investigator effective ; 9 ) concomitant daily treatment opioid analgesic , sedative hypnotic , know CNS depressant ; 10 ) know hypersensitivity cannabinoids sesame oil ; 11 ) disease gastrointestinal system , liver , kidney may impede metabolism excretion CBD ; 12 ) inability read write English ; 13 ) history seizure , head trauma history CNS insult could predispose subject seizure ; 14 ) currently take valproic acid , lamotrigine , propranolol , medication metabolize UGT1A9 UGT2B7 enzyme ( CBD may affect UGT level ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Cannabidiol</keyword>
</DOC>